Roche, Novartis Lose French Court Battle Over Off-Label Use Of Avastin In AMD
Executive Summary
Roche and Novartis have been unsuccessful in their attempt to stop the French authorities using Avastin off label in wet AMD for financial reasons.
You may also be interested in...
First Lucentis Biosimilar Among Drugs Awaiting Verdict On EU Approval Filings
Sponsors of several new medicines, including the first ever CAR-T for multiple myeloma, will find out this week if their products are on track to get EU marketing authorizations. Also, three sponsors might be asked to address outstanding issues about their products in the final stages of review.
UK Court Ruling Ends Novartis/Bayer Crusade Against Avastin In AMD
AMD patients in the UK can legitimately be given compounded bevacizumab (Roche’s Avastin) after the appeals court said NHS trusts could offer a drug off-label for economic reasons where there were no safety or efficacy concerns.
English Court Queries EMA Primacy & Says Avastin Can Be Used In AMD
The English High Court has rejected attempts by Novartis and Roche to stop clinical commissioning groups from offering Avastin to wet AMD patients in a cost-containment move. In a development that has alarmed pharma firms, the court also questioned the exclusive role of the European Medicines Agency in marketing authorizations, saying that CCGs as well as the health technology assessment body, NICE, have competences in that area, and called on the UK regulator to review its guidance on off-label and unlicensed use.